Litigation Over Patent Linkage Regulations In Canada
Litigation Over Patent Linkage Regulations In Canada – Detailed Explanation With Case Laws
1. Introduction
Litigation over Patent Linkage Regulations in Canada concerns legal disputes arising from the relationship between pharmaceutical patent rights and the regulatory approval of generic medicines.
The Canadian patent linkage system is primarily governed by the Patented Medicines (Notice of Compliance) Regulations (PM(NOC) Regulations). These Regulations seek to balance pharmaceutical innovation with generic competition and public access to affordable medicines.
2. Legal Framework
The principal legal provisions include:
Patent Act, R.S.C. 1985, c. P-4.
Section 42: Rights granted to patent holders.
Section 55: Liability for patent infringement.
Section 57: Remedies for infringement.
Section 55.2: Regulatory review exception.
Patented Medicines (Notice of Compliance) Regulations, SOR/93-133.
Food and Drugs Act.
3. Meaning of Patent Linkage Litigation
Patent linkage litigation arises when a pharmaceutical patent owner challenges a generic manufacturer's allegation that its proposed medicine does not infringe a listed patent or that the patent is invalid.
The litigation generally involves questions of patent validity, infringement, patent listing eligibility and generic market entry.
4. Procedure
The generic manufacturer files a drug submission with Health Canada.
Relevant patents listed on the Patent Register are identified.
The generic manufacturer serves a Notice of Allegation where required.
The innovator may commence proceedings under section 6 of the Regulations.
The Federal Court examines infringement and validity issues.
The Court issues an appropriate judgment or remedy.
5. Major Grounds for Litigation
A. Patent Infringement
Innovators may claim that the generic product or its manufacture, use or sale infringes valid patent claims.
B. Patent Invalidity
Generic manufacturers may challenge patents on grounds of lack of novelty, obviousness, insufficient disclosure, lack of utility or double patenting.
C. Improper Patent Listing
Disputes may arise where a patent does not satisfy the statutory requirements for inclusion on the Patent Register.
D. Delayed Generic Entry
Section 8 provides a compensation mechanism in qualifying circumstances where generic manufacturers suffer losses because of delayed market entry.
E. Abuse of Patent Linkage
Litigation may concern allegations that patent listing or repeated proceedings have been used to delay generic competition improperly.
6. Important Case Laws
1. Apotex Inc. v. Canada (Attorney General), 2000 CanLII 17118 (FCA)
The Federal Court of Appeal upheld the validity of the Patented Medicines (Notice of Compliance) Regulations.
Legal Principle: Patent linkage regulations are valid when adopted within the authority delegated by Parliament.
2. Bristol-Myers Squibb Co. v. Canada (Attorney General), 2005 SCC 26
The Supreme Court considered the interpretation and application of the pharmaceutical patent linkage framework.
Legal Principle: Patent linkage regulations must be interpreted according to their text, context and purpose.
3. AstraZeneca Canada Inc. v. Canada (Minister of Health), 2006 SCC 49
The dispute concerned the listing of pharmaceutical patents and the scope of patent linkage protection.
The Supreme Court rejected an interpretation that would extend the regulatory protection beyond the limits established by the Regulations.
Legal Principle: Patent owners must satisfy the statutory conditions for patent listing and cannot automatically use the linkage system to delay generic entry.
4. Merck Frosst Canada Ltd. v. Canada (Minister of Health), 2012 SCC 3
The Supreme Court examined disclosure of commercially confidential pharmaceutical regulatory information under access-to-information legislation.
Legal Principle: Confidential pharmaceutical information must be assessed under the applicable statutory requirements.
5. Apotex Inc. v. Sanofi-Aventis, 2014 SCC 67
The dispute concerned the validity of Sanofi's clopidogrel patent.
The Supreme Court explained the legal framework for determining obviousness in patent law.
Legal Principle: Pharmaceutical patents must satisfy the ordinary requirements of patent validity.
6. Apotex Inc. v. Eli Lilly and Company – Atomoxetine Litigation
The dispute concerned patent linkage proceedings relating to atomoxetine and compensation for delayed generic market entry.
Legal Principle: Section 8 compensation and additional remedies must be assessed according to the applicable statutory and common-law principles.
7. Impact of the 2017 Amendments
The amendments effective September 21, 2017 significantly changed the Canadian patent linkage system.
Major changes include:
Introduction of a fuller infringement and validity action.
Greater opportunity for final judicial determinations.
Retention of section 8 compensation.
Improved procedural fairness.
Greater accountability in patent enforcement.
The amendments replaced the former prohibition-application model with a more comprehensive litigation framework.
8. Role of the Federal Court
The Federal Court performs important functions, including:
Determining patent infringement.
Examining patent validity.
Interpreting pharmaceutical patent claims.
Resolving patent listing disputes.
Assessing damages.
Granting appropriate declarations and injunctions.
9. Remedies Available
The remedies may include:
Declaration of patent infringement.
Declaration of patent invalidity.
Injunctions.
Monetary damages.
Section 8 compensation.
Litigation costs.
10. Challenges
Major challenges include:
Delayed generic competition.
Complex pharmaceutical patent interpretation.
Patent evergreening concerns.
High litigation costs.
Uncertainty in calculating damages.
Coordination between regulatory approval and patent enforcement.
11. Importance
Patent linkage litigation is important because it:
Protects legitimate pharmaceutical patent rights.
Provides a mechanism for resolving innovator-generic disputes.
Supports pharmaceutical competition.
Encourages genuine innovation.
Promotes access to affordable medicines.
Clarifies the relationship between patent law and pharmaceutical regulation.
12. Conclusion
Litigation over Patent Linkage Regulations in Canada represents an important intersection between intellectual property law, pharmaceutical regulation and competition policy.
The Patented Medicines (Notice of Compliance) Regulations establish a specialized framework for resolving disputes between pharmaceutical innovators and generic manufacturers.
Judicial decisions such as Apotex Inc. v. Canada (Attorney General), Bristol-Myers Squibb Co. v. Canada (Attorney General), and AstraZeneca Canada Inc. v. Canada (Minister of Health) have helped define the scope and interpretation of the Canadian patent linkage system.
The 2017 amendments strengthened the framework by introducing a more comprehensive process for determining patent infringement and validity.
Ultimately, Canadian patent linkage law seeks to balance pharmaceutical innovation, patent protection, generic competition and public access to affordable medicines.
13. Important Statutory References
Patent Act, R.S.C. 1985, c. P-4.
Section 42 – Rights granted by patents.
Section 55 – Patent infringement liability.
Section 57 – Remedies.
Section 55.2 – Regulatory review exception.
Patented Medicines (Notice of Compliance) Regulations.
Section 5 – Generic drug submissions.
Section 6 – Patent litigation.
Section 8 – Compensation for delayed market entry.
Food and Drugs Act.
Note: This explanation is for academic purposes. The current statutory provisions and relevant judicial decisions should be checked before relying on them in legal proceedings.

comments